Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REDO-JAK: Dose REDuction Of JAnus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

NCT07160231 is registered in ClinicalTrials.gov with Sint Maartenskliniek as lead sponsor.

NCT NCT07160231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07160231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REDO-JAK: Dose REDuction Of JAnus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
Lead sponsor
Sint Maartenskliniek
Phase
Phase 4
Overall status
Recruiting
Start date
September 15, 2025
Completion date
May 1, 2028
Enrollment
200 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis (axspa), psoriatic arthritis (psa), rheumatoid arthritis (ra)